Global measles resurgence 2026
Analysis based on 7 articles · First reported Aug 21, 2026 · Last updated Aug 21, 2026
The global measles resurgence increases demand for measles vaccines, potentially benefiting vaccine manufacturers, but also strains public health budgets and could lead to higher healthcare costs. Funding cuts to Gavi may reduce vaccine procurement in low-income countries, impacting global health markets and potentially increasing disease burden.
In 2026, the World Health Organization estimates that nearly 11 million people worldwide will contract measles, with most cases in Africa and Asia, but significant outbreaks also in the Americas and Europe. The resurgence is driven by decreased vaccination rates, including supply shortages in low-income countries and vaccine hesitancy in high-income countries. Bangladesh reports the most cases and over 900 deaths, exacerbated by political instability and vaccine procurement issues. In the Americas, Guatemala has over 30,000 cases, linked to an anti-vaccine megachurch gathering, while Canada lost its measles elimination status and the U.S. faces its worst year since 1991. Funding cuts by France, Germany, the U.K., and the U.S. have created a budget shortfall for GAVI, threatening vaccine supply for lower-income countries.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard